Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent
CompanyDeals

Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent

Trump Signs Executive Order to Withdraw from WHO, Drawing Criticism
Policy / Regulatory

Trump Signs Executive Order to Withdraw from WHO, Drawing Criticism

Douyin Gains Approval to Establish Hospital in Beijing's Zhongguancun
Hospital

Douyin Gains Approval to Establish Hospital in Beijing’s Zhongguancun

NMPA Approves Synaptic Medical's Cryoablation Device and Gene Methylation Detection Kit
CompanyMedical Device

NMPA Approves Synaptic Medical’s Cryoablation Device and Gene Methylation Detection Kit

Huadong Medicine's MediBeacon TGFR System Receives FDA Marketing Clearance
CompanyDrug

Huadong Medicine’s MediBeacon TGFR System Receives FDA Marketing Clearance

MediLink's YL201 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma
CompanyDrug

MediLink’s YL201 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma

Jiangsu Lianhuan Completes Enrollment for Phase III Study of LH-1801 in Type 2 Diabetes
CompanyDrug

Jiangsu Lianhuan Completes Enrollment for Phase III Study of LH-1801 in Type 2 Diabetes

Arrowhead's Plozasiran Accepted for FDA Review in Familial Chylomicronemia Syndrome
CompanyDrug

Arrowhead’s Plozasiran Accepted for FDA Review in Familial Chylomicronemia Syndrome

Keymed and InnoCare Announce Licensing Deal for CD20xCD3 Bispecific Antibody with Prolium
CompanyDeals

Keymed and InnoCare Announce Licensing Deal for CD20xCD3 Bispecific Antibody with Prolium

GSK's Jemperli Approved for First-Line Endometrial Cancer Treatment in EU
CompanyDrug

GSK’s Jemperli Approved for First-Line Endometrial Cancer Treatment in EU

Kelun-Biotech's Tagitanlimab Receives NMPA Clearance for Nasopharyngeal Carcinoma
CompanyDrug

Kelun-Biotech’s Tagitanlimab Receives NMPA Clearance for Nasopharyngeal Carcinoma

Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets
CompanyDeals

Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets